These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. Pinyon RA; Paton JC; Paton AW; Botten JA; Morona R J Infect Dis; 2004 May; 189(9):1547-55. PubMed ID: 15116289 [TBL] [Abstract][Full Text] [Related]
7. Protective immunization of mice with an active-site mutant of subtilase cytotoxin of Shiga toxin-producing Escherichia coli. Talbot UM; Paton JC; Paton AW Infect Immun; 2005 Jul; 73(7):4432-6. PubMed ID: 15972544 [TBL] [Abstract][Full Text] [Related]
8. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Bielaszewska M; Friedrich AW; Aldick T; Schürk-Bulgrin R; Karch H Clin Infect Dis; 2006 Nov; 43(9):1160-7. PubMed ID: 17029135 [TBL] [Abstract][Full Text] [Related]
9. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Smith MJ; Teel LD; Carvalho HM; Melton-Celsa AR; O'Brien AD Vaccine; 2006 May; 24(19):4122-9. PubMed ID: 16551486 [TBL] [Abstract][Full Text] [Related]
10. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Nishikawa K; Matsuoka K; Kita E; Okabe N; Mizuguchi M; Hino K; Miyazawa S; Yamasaki C; Aoki J; Takashima S; Yamakawa Y; Nishijima M; Terunuma D; Kuzuhara H; Natori Y Proc Natl Acad Sci U S A; 2002 May; 99(11):7669-74. PubMed ID: 12032341 [TBL] [Abstract][Full Text] [Related]
11. Virulence profiles of Shiga toxin 2e-producing Escherichia coli isolated from healthy pig at slaughter. Zweifel C; Schumacher S; Beutin L; Blanco J; Stephan R Vet Microbiol; 2006 Oct; 117(2-4):328-32. PubMed ID: 16872761 [TBL] [Abstract][Full Text] [Related]
12. Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli strains that are virulent for humans. Paton AW; Srimanote P; Woodrow MC; Paton JC Infect Immun; 2001 Nov; 69(11):6999-7009. PubMed ID: 11598075 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and assessment of globotriose-chitosan conjugate, a novel inhibitor of shiga toxins produced by Escherichia coli. Li X; Wu P; Cheng S; Lv X J Med Chem; 2012 Mar; 55(6):2702-10. PubMed ID: 22372889 [TBL] [Abstract][Full Text] [Related]
19. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome. Goldwater PN Expert Rev Anti Infect Ther; 2007 Aug; 5(4):653-63. PubMed ID: 17678428 [TBL] [Abstract][Full Text] [Related]
20. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli. Cilmi SA; Karalius BJ; Choy W; Smith RN; Butterton JR J Infect Dis; 2006 Oct; 194(8):1135-40. PubMed ID: 16991089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]